Man Yan, Ge Chuan-Qin, Li Zeng-Zheng, Yang Tong-Hua, Wang Ya-Jie
Department of Hematology, The Affiliated Hospital of Kunming University of Science and Technology, The First People's Hospital of Yunnan Province, Kunming 650500, Yunnan Province, China.
Department of Hematology, The Affiliated Hospital of Kunming University of Science and Technology, The First People's Hospital of Yunnan Province, Kunming 650500, Yunnan Province, China.E-mail:
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2023 Aug;31(4):1050-1055. doi: 10.19746/j.cnki.issn.1009-2137.2023.04.019.
To investigate the expression and prognostic value of cytokines in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL).
Clinical data of 62 patients diagnosed with DLBCL in the First People's Hospital of Yunnan Province from June 2017 to November 2018 were collected. The differences in expression levels of 14 serum cytokines [interleukin (IL)-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12p70, IL-17A, IL-17F, IL-22, interferon (IFN)-γ, tumor necrosis factor (TNF)-α, TNF-β] in patients with different survival outcomes, and the impact of the cytokines on 3-year progression-free survival (PFS) and 3-year overall survival (OS) of patients with DLBCL were analyzed retrospectively.
Among the 14 cytokines, only the expression of IL-10 was significantly different in patients with different survival outcomes ( =0.007). According to the receiver operating characteristic (ROC) curve, the optimal cut-off value for IL-10 was 11.74 pg/ml. Serum IL-10 was positively correlated with infection markers procalcitonin (PCT) ( =0.321, =0.029), C-reactive protein (CRP) ( =0.320, =0.013) and tumor burden index lactate dehydrogenase (LDH) ( =0.439, <0.001) in newly diagnosed DLBCL patients. The level of IL-10 in patients with pulmonary infection was significantly higher than that in patients without pulmonary infection ( =0.012). However, there was no statistically significant difference on the 3-year survival outcomes between patients with or without pulmonary infection. There was no significant difference in IL-10 level in patients with different Ann Arbor stages ( >0.05). Patients with high IL-10 level (IL-10>11.74 pg/ml) had significantly higher LDH level than those with low IL-10 level (IL-10≤11.74 pg/ml) ( <0.001). The 3-year PFS rate and 3-year OS rate of DLBCL patients with high IL-10 level were significantly lower than those of low IL-10 level group [(44.4±11.7)% (81.8±5.8)%, <0.001; (61.6±11.5)% (93.2±3.8)%, =0.001].
Serum IL-10 level in newly diagnosed DLBCL patients can reflect the inflammatory state of the body, which may be related to tumor load. Newly diagnosed DLBCL patients with serum IL-10>11.74 pg/ml have higher early mortality and worse prognosis.
探讨细胞因子在新诊断的弥漫性大B细胞淋巴瘤（DLBCL）患者中的表达及预后价值。
收集2017年6月至2018年11月在云南省第一人民医院确诊为DLBCL的62例患者的临床资料。回顾性分析14种血清细胞因子[白细胞介素（IL）-1β、IL-2、IL-4、IL-5、IL-6、IL-8、IL-10、IL-12p70、IL-17A、IL-17F、IL-22、干扰素（IFN）-γ、肿瘤坏死因子（TNF）-α、TNF-β]在不同生存结局患者中的表达水平差异，以及这些细胞因子对DLBCL患者3年无进展生存期（PFS）和3年总生存期（OS）的影响。
在14种细胞因子中，只有IL-10的表达在不同生存结局的患者中有显著差异（P = 0.007）。根据受试者工作特征（ROC）曲线，IL-10的最佳截断值为11.74 pg/ml。新诊断的DLBCL患者血清IL-10与感染标志物降钙素原（PCT）（r = 0.321，P = 0.029）、C反应蛋白（CRP）（r = 0.320，P = 0.013）和肿瘤负荷指标乳酸脱氢酶（LDH）（r = 0.439，P < 0.001）呈正相关。肺部感染患者的IL-10水平显著高于无肺部感染患者（P = 0.012）。然而，有无肺部感染患者的3年生存结局差异无统计学意义。不同Ann Arbor分期患者的IL-10水平差异无统计学意义（P > 0.05）。IL-10水平高（IL-10>11.74 pg/ml）的患者LDH水平显著高于IL-10水平低（IL-10≤11.74 pg/ml）的患者（P < 0.001）。IL-10水平高的DLBCL患者的3年PFS率和3年OS率显著低于IL-10水平低的组[（44.4±11.7）%对（81.8±5.8）%，P < 0.001；（61.6±11.5）%对（'93.2±3.8）%，P = 0.001]。
新诊断的DLBCL患者血清IL-10水平可反映机体炎症状态，可能与肿瘤负荷有关。血清IL-10>11.74 pg/ml的新诊断DLBCL患者早期死亡率较高，预后较差。
